Exposure during pregnancy to Il-1 targeted therapies and pregnancy, foetal and neonatal outcomes: a study from the French Teratology Information Service
In this study, the largest series to date, our results do not suggest occurrence of specific negative outcomes in pregnancies exposed to anti-IL-1. The imputability of anakinra in the malformations observed is unlikely. If needed, their use during pregnancy should be considered.
Authors
- Catherine Vauzelle
- Bruno Fautrel (ORCID: https://orcid.org/0000-0001-8845-4274)
- Benôıt Marin (ORCID: https://orcid.org/0000-0001-8857-0910)
- Bénédicte Coulm (ORCID: https://orcid.org/0000-0003-3138-1654)
- Élisabeth Éléfant
- Valentine Faure‐Bardon (ORCID: https://orcid.org/0000-0002-7510-9364)
- Mathilde Latour
- Delphine Beghin
- Camille Reinaud
Institutions
- Inserm (FR)
- Université Sorbonne Nouvelle (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Centre d'Économie de la Sorbonne (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1093/rheumatology/keaf387
- Citations
- 1
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 1.88